Skip to main content
Erschienen in:

11.02.2022 | Original Article

Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan

verfasst von: Takayuki Ikezoe, Hideyoshi Noji, Yasutaka Ueda, Yoshinobu Kanda, Shinichiro Okamoto, Kensuke Usuki, Takahisa Matsuda, Hirozumi Akiyama, Akihiko Shimono, Yuji Yonemura, Tatsuya Kawaguchi, Shigeru Chiba, Yuzuru Kanakura, Jun‑ichi Nishimura, Haruhiko Ninomiya, Naoshi Obara

Erschienen in: International Journal of Hematology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

All Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab were enrolled in post-marketing surveillance (PMS) between June 2010 and August 2019 to assess the long-term effectiveness and safety of eculizumab. The reduction in intravascular hemolysis, the change in hemoglobin (Hb) level, and the change in renal function were assessed to determine the effectiveness of eculizumab. The types and frequencies of adverse events (AEs) were assessed to determine its safety. A total of 632 patients were enrolled and the median treatment duration was 3.6 years. Treatment with eculizumab significantly reduced lactate dehydrogenase (LDH) levels and significantly increased Hb levels. These changes were maintained for up to 5 years of treatment. An estimated glomerular filtration rate ≥ 60 ml/min/1.73 m2 and higher LDH level at baseline were associated with increases in Hb levels during eculizumab treatment. The overall incidence of any AE was 69.92/100 patient-years. Hemolysis was the most common AE (6.43/100 patient-years). The incidence of infection-related AEs was 20.57/100 patient-years, and included meningococcal infection in three patients (0.12/100 patient-years). This long-term follow-up of patients with PNH demonstrated the sustained effectiveness of eculizumab and supports its well-established safety profile.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Devalet B, Mullier F, Chatelain B, Dogné J-M, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95:190–8.CrossRef Devalet B, Mullier F, Chatelain B, Dogné J-M, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95:190–8.CrossRef
2.
Zurück zum Zitat Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–7.CrossRef Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–7.CrossRef
3.
Zurück zum Zitat Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.CrossRef Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.CrossRef
4.
Zurück zum Zitat Nishimura J-I, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.CrossRef Nishimura J-I, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.CrossRef
5.
Zurück zum Zitat Brodsky R. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, et al., editors. Hematology basic principles and practices. 4th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 419–27. Brodsky R. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, et al., editors. Hematology basic principles and practices. 4th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 419–27.
6.
Zurück zum Zitat Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–11.CrossRef Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–11.CrossRef
7.
Zurück zum Zitat Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–6.CrossRef Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–6.CrossRef
8.
Zurück zum Zitat Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program. 2016;2016:208–16.CrossRef Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program. 2016;2016:208–16.CrossRef
10.
Zurück zum Zitat Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181–92.CrossRef Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181–92.CrossRef
11.
Zurück zum Zitat Ministry of Health, Labour and Welfare. Specific Disease Treatment Research Project Research to understand the epidemiological image of untargeted diseases (number of patients, distribution of patients, age, life prognosis, degree of daily life disorders). https://mhlw-grants.niph.go.jp/project/3542/1. Accessed Sept 15, 2021 (in Japanese). Ministry of Health, Labour and Welfare. Specific Disease Treatment Research Project Research to understand the epidemiological image of untargeted diseases (number of patients, distribution of patients, age, life prognosis, degree of daily life disorders). https://​mhlw-grants.​niph.​go.​jp/​project/​3542/​1. Accessed Sept 15, 2021 (in Japanese).
12.
Zurück zum Zitat Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107:656–65.CrossRef Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107:656–65.CrossRef
13.
Zurück zum Zitat Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–401.CrossRef Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–401.CrossRef
14.
Zurück zum Zitat Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.CrossRef Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.CrossRef
15.
Zurück zum Zitat Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.CrossRef Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.CrossRef
16.
Zurück zum Zitat Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548–58.CrossRef Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548–58.CrossRef
17.
Zurück zum Zitat Ham TH, Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Investig. 1939;18:657–72.CrossRef Ham TH, Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Investig. 1939;18:657–72.CrossRef
18.
Zurück zum Zitat Hartmann RC, Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1966;275:155–7.CrossRef Hartmann RC, Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1966;275:155–7.CrossRef
19.
Zurück zum Zitat Nishimura J, Kanakura Y. Paroxysmal nocturnal hemoglobinuria. In: Ozawa K, et al., editors. Guidelines for the diagnosis and treatment of intractable anemia. Tokyo: Nankodo; 2011. p. 93–130. Nishimura J, Kanakura Y. Paroxysmal nocturnal hemoglobinuria. In: Ozawa K, et al., editors. Guidelines for the diagnosis and treatment of intractable anemia. Tokyo: Nankodo; 2011. p. 93–130.
20.
Zurück zum Zitat Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–65.CrossRef Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–65.CrossRef
21.
Zurück zum Zitat Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–9.CrossRef Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–9.CrossRef
22.
Zurück zum Zitat Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.CrossRef Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.CrossRef
23.
Zurück zum Zitat Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98:406–16.CrossRef Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98:406–16.CrossRef
24.
Zurück zum Zitat Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36–46.CrossRef Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36–46.CrossRef
25.
Zurück zum Zitat Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92.CrossRef Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92.CrossRef
26.
Zurück zum Zitat Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol. 2021;96:E232–5.CrossRef Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol. 2021;96:E232–5.CrossRef
27.
Zurück zum Zitat Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One. 2015;10:e0125215.CrossRef Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One. 2015;10:e0125215.CrossRef
28.
Zurück zum Zitat Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol. 2009;13:614–20.CrossRef Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol. 2009;13:614–20.CrossRef
29.
Zurück zum Zitat Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553–9.CrossRef Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553–9.CrossRef
30.
Zurück zum Zitat de Latour RP, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–83.CrossRef de Latour RP, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–83.CrossRef
31.
Zurück zum Zitat Brodsky RA, de Latour RP, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106:230–7.CrossRef Brodsky RA, de Latour RP, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106:230–7.CrossRef
32.
Zurück zum Zitat Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10:455–64.CrossRef Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10:455–64.CrossRef
33.
Zurück zum Zitat Rho H, Wells RA. Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Orphan Drug. 2020;8:257–64.CrossRef Rho H, Wells RA. Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Orphan Drug. 2020;8:257–64.CrossRef
34.
Zurück zum Zitat Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2:2176–85.CrossRef Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2:2176–85.CrossRef
35.
Zurück zum Zitat Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13:e0195909.CrossRef Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13:e0195909.CrossRef
36.
Zurück zum Zitat Kulasekararaj AG, Hill A, Rottinghaus ST, Langermeijer S, Wells R, Ataulfo Gonzalez-Fernandez F, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540–9.CrossRef Kulasekararaj AG, Hill A, Rottinghaus ST, Langermeijer S, Wells R, Ataulfo Gonzalez-Fernandez F, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540–9.CrossRef
38.
Zurück zum Zitat Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1–41.CrossRef Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1–41.CrossRef
39.
Zurück zum Zitat McNamara LA, Topaz N, Wang X, Hariri S, Fox LA, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734–7.CrossRef McNamara LA, Topaz N, Wang X, Hariri S, Fox LA, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734–7.CrossRef
Metadaten
Titel
Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan
verfasst von
Takayuki Ikezoe
Hideyoshi Noji
Yasutaka Ueda
Yoshinobu Kanda
Shinichiro Okamoto
Kensuke Usuki
Takahisa Matsuda
Hirozumi Akiyama
Akihiko Shimono
Yuji Yonemura
Tatsuya Kawaguchi
Shigeru Chiba
Yuzuru Kanakura
Jun‑ichi Nishimura
Haruhiko Ninomiya
Naoshi Obara
Publikationsdatum
11.02.2022
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 4/2022
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-022-03287-y

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.